• Recruiting

NCT05172596: Phase 2: PHE885 CAR-T Therapy in Adult Participants With Relapsed Refractory Myeloma

Updated: May 24


NCT05172596: Phase 2: PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma


phe885

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma


This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cells, manufactured with a new process. CAR-T cells will be investigated as a single agent in relapsed and refractory multiple myeloma


Sponsor

Novartis Pharmaceuticals

 

ClinicalTrials.gov Identifier: NCT05172596


Official Title: Phase II, Open Label, Study of PHE885, a B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma


First Posted : December 29, 2021


Click here to see details on ClinicalTrials.gov

 

Biological: PHE885


BCMA-directed Autologous CAR-T Cells PHE885


Autologous Anti-BCMA CAR T-cells PHE885 (Code C174124)

Autologous Anti-BCMA CAR T-cells PHE885

Autologous BCMA-specific CAR T-cells PHE885

BCMA-directed Autologous CAR-T Cells PHE885

PHE 885

PHE-885

PHE885

 

Locations

Australia, Melbourne

Singapore






Posts Archive